scPharmaceuticals Inc
NASDAQ:SCPH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Torishima Pump Mfg Co Ltd
TSE:6363
|
JP |
|
GMR Airports Infrastructure Ltd
BSE:532754
|
IN |
|
Overseas Education Ltd
SGX:RQ1
|
SG |
|
Agripower France SASU
PAR:ALAGP
|
FR |
scPharmaceuticals Inc
Interest Expense
scPharmaceuticals Inc
Interest Expense Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Interest Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
scPharmaceuticals Inc
NASDAQ:SCPH
|
Interest Expense
$6.1m
|
CAGR 3-Years
40%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Interest Expense
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Interest Expense
$1.9B
|
CAGR 3-Years
15%
|
CAGR 5-Years
6%
|
CAGR 10-Years
26%
|
|
|
Pfizer Inc
NYSE:PFE
|
Interest Expense
$2.7B
|
CAGR 3-Years
29%
|
CAGR 5-Years
13%
|
CAGR 10-Years
8%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Interest Expense
$1.4B
|
CAGR 3-Years
12%
|
CAGR 5-Years
10%
|
CAGR 10-Years
7%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Interest Expense
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
scPharmaceuticals Inc
Glance View
scPharmaceuticals, Inc. engages in the development of transformative pharmaceutical products for subcutaneous delivery. The company is headquartered in Burlington, Massachusetts and currently employs 26 full-time employees. The company went IPO on 2017-11-17. The firm is focused on exploring, developing and commercializing products that expand and advance the outpatient care of acute conditions, including worsening heart failure and bacterial infections requiring outpatient parenteral antimicrobial therapy. Its lead product candidate, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infusor and is under development for treatment of congestion in patients with heart failure who display reduced responsiveness to oral diuretics and do not require hospitalization. Its area of focus is congestion in heart failure and outpatient parenteral antimicrobial therapy (OPAT). Its pipeline programs include FUROSCIX, scCeftriaxone and scCarbapenem. Its FUROSCIX On-Body Infusor is a drug-device combination product consisting of FUROSCIX. The firm's wholly owned subsidiary is scPharmaceuticals Securities Corporation.
See Also
What is scPharmaceuticals Inc's Interest Expense?
Interest Expense
6.1m
USD
Based on the financial report for Jun 30, 2025, scPharmaceuticals Inc's Interest Expense amounts to 6.1m USD.
What is scPharmaceuticals Inc's Interest Expense growth rate?
Interest Expense CAGR 5Y
21%
Over the last year, the Interest Expense growth was -27%. The average annual Interest Expense growth rates for scPharmaceuticals Inc have been 40% over the past three years , 21% over the past five years .
